46
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Combination of icotinib, surgery, and internal-radiotherapy of a patient with lung cancer severely metastasized to the vertebrae bones with EGFR mutation: a case report

, , &
Pages 1271-1276 | Published online: 02 Jun 2015

References

  • HuSXieGZhangDXSynthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitorsBioorg Med Chem Lett201422196301630522959248
  • DeleaTLangerCMckiernanJThe cost of treatment of skeletal-related events in patients with bone metastases from lung cancerOncology2004675–639039615713995
  • LorussoVDuranIGarzon-RodriquezCHealth resource utilization associated with skeletal-related events in European patients with lung cancer: A subgroup analysis from a prospective multinational studyMol Clin Oncol20142570170825054033
  • SugiuraHYamadaKSugiuraTHidaTMitsudomiTPredictors of survival in patients with bone metastasis of lung cancerClin Orthop Relat Res2008466372973618196360
  • NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) (Version 3. 2014) http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Date: 2014.04.17
  • WangJNongJJiaHEfficacy and predictors of EGFR tyrosine kinase inhibitors in Chinese advanced lung adenocarcinoma: analyses of 253 cases from a single instituteOncol Res201421523724624854100
  • PaezJGJanneALeeJCEGFR mutations in lung cancer correlation with clinical response to gefitinib therapyScience200430456761497150015118125
  • WenhuaLiangJinShengXuanWuExon 19 deletion association with progression-free survival compared to L858R mutation at exon 21 in treatment with first-line EGFR-TKIs: A meta-analysis of subgroup data from eight phase III randomized controlled trials. 2014 ASCO Annual Meeting AbstractsJournal of Clinical Oncology20143215 Suppl8107
  • ZhaoQShentuJXuNPhase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor in patients with advanced NSCLC and other solid tumorsLung Cancer201173219520221144613
  • ShiYZhangLLiuXIcotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trialLancet Oncol2013141095396123948351
  • GuanYZhaoHMengJYanXJiaoSDramatic response to high-dose icotinib in a lung adenocarcinoma patient after erlotinib failureLung Cancer201483230530724370197
  • SimmonsEDZhengYVertebral tumors: surgical versus nonsurgical treatmentClin Orthop Relat Res200644323324716462447
  • BartelsRHvan der LindenYMvan der GraafWTSpinal extradural metastasis: review of current treatment optionsCA Cancer J Clin200858424525918354080
  • BhattADShulerJCBoakyeMWooSYCurrent and emerging concepts in non-invasive and minimally invasive management of spine metastasisCancer Treat Rev201339214215222959872
  • ChoiDKimTGSungYCThe past, present, and future of adoptive I cell therapyImmune Netw201212413914723091437
  • SangioloDCytokine induced killer cells as promising immunotherapy for solid tumorsJ Cancer2011236336821716717
  • ShiSBTangXYTianJEfficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancerJ Immunother201437425025524714359